Commonwealth Equity Services
INZY

Commonwealth Equity Services’s Inozyme Pharma INZY Stock Holding History

Commonwealth Equity Services’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-65,781
Closed -$762K – 3691
2021
Q3 		$762K Hold
65,781
– – ﹤0.01% 2140
2021
Q2 		$1.12M Hold
65,781
– – ﹤0.01% 1832
2021
Q1 		$1.3M Buy
+65,781
New +$1.45M ﹤0.01% 1613

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Commonwealth Equity Services's INZY Position: Q4 2021 in Review

Commonwealth Equity Services sold out of Inozyme Pharma (INZY) in Q4 2021, closing a stake of 65,781 shares — an estimated $762K sold.

Commonwealth Equity Services first reported a position in INZY in Q1 2021 and held it in 3 quarters. The position peaked at $1.3M in Q1 2021. 51 funds tracked by Wall St. Rank hold INZY as of Q4 2021.

  • Commonwealth Equity Services reported no remaining Inozyme Pharma position as of Q4 2021 after selling out during the quarter.
  • Commonwealth Equity Services sold 65,781 Inozyme Pharma shares in Q4 2021, an estimated $762K.
  • Commonwealth Equity Services first reported a position in Inozyme Pharma in Q1 2021 and held it in 3 quarters.
  • Commonwealth Equity Services's Inozyme Pharma position peaked at $1.3M in Q1 2021.
  • 51 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2021.

Based on Commonwealth Equity Services's 13F filing for Q4 2021, filed 31 Jan 2022.